Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer

von K. R. Zeinalova, Ya. V. Vishnevskaya, I. P. Ganshina
Veröffentlicht 2014-07-01

Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

von O. O. Gordeeva, L. G. Zhukova, I. V. Kolyadina, I. P. Ganshina
Veröffentlicht 2019-04-01

Ribociclib in 1st line HR+ breast cancer treatment

von L G Zhukova, I P Ganshina, O O Gordeeva, E V Lubennikova
Veröffentlicht 2018-06-01

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

von L G Zhukova, I P Ganshina, E I Khatkova, T E Tikhomirova, O E Kondratyeva
Veröffentlicht 2018-06-01

Olaparib in the metastatic HER2-negative breast cancer setting

von L. G. Zhukova, E. I. Khatkova, I. P. Ganshina, I. V. Kolyadina, E. V. Lubennikova
Veröffentlicht 2020-12-01

Dermatomyositis and polymyositis in breast cancer patients: a case reports

von I P Ganshina, L G Zhukova, E Z Burnevitch, O O Gordeeva, O E Kondratieva
Veröffentlicht 2018-03-01

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

von I. P. Ganshina, D. A. Filonenko, O. O. Gordeeva, E. V. Lubennikova, I. V. Kolyadina, A. A. Mescheryakov
Veröffentlicht 2019-06-01

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer

von D.  A. Morozov, I. V. Kolyadina, I. V. Poddubnaya, I.  P. Ganshina, S. V. Khokhlova, V. V. Kometova, V. V. Rodionov
Veröffentlicht 2022-01-01

ASSOCIATION OF NKT- AND ACTIVATED CD25⁺ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS

von A. I. Chertkova, E. G. Slavina, T. N. Zabotina, Z. G. Kadagidze, E. K. Shoua, O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Gan’shina, A. A. Meshcheryakov
Veröffentlicht 2020-12-01

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

von O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov
Veröffentlicht 2020-11-01

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

von E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, L. G. Zhukova
Veröffentlicht 2017-11-01

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

von T. Yu. Semiglazova, E. V. Lubennikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, A. V. Avramenko, E. V. Artemeva, S. A. Borozdina, A. A. Vakhitova, N. M. Volkov, I. P. Ganshina, Sh. A. Dzhalilova, L. G. Zhukova, B. S. Kasparov, A. A. Kachmazov, V. V. Klimenko, A. i. Kornietskaya, A. A. Meshcheryakov, A. A. Paichadze, A. N. Poltoratsky, O. E. Ryabishina, M. L. Stepanova, E. N Imyanitov
Veröffentlicht 2020-12-01